CAR-T Therapy: Syndrome Released by Cytokine

CAR-T cell therapy has brought hope of a cure to a large number of cancer patients in recent years. Despite its outstanding effectiveness, the toxicity known as cytokine release syndrome (CRS) remains a serious problem.

Once CAR-T has been infused into the human body, this activates T lymphocytes, which rapidly proliferate, prompting an excessive release of cytokines such as TNF-α, IFN-γ, IL-1, IL-2, IL-4, IL-6, IL-8, IL-10, and IL-12.

This cytokine release can result in a number of outcomes, for example, dyspnea, hypotension, myalgia, fever, blood coagulation disorders, and end-organ dysfunction. These outcomes have the potential to cause permanent damage to organs and tissues, even resulting in death.

While CRS is an acute systemic inflammatory syndrome associated with CAR-T cell therapy,1 a number of factors can impact a patient’s chances of having CRS. These include treatment procedure, disease state, and drugs2 (Table 1).

Table 1. Risk factors for CRS. Source: ACROBiosystems

CAR-T Therapy: Syndrome Released by Cytokine

Clinical identification of CRS onset

CRS patients tend to exhibit increased levels of ferritin and serum CRP, meaning that these may be utilized as biomarkers when determining the occurrence of CRS.

Each of these markers, including ferritin, LDH, CRP, AST, ALT, and creatinine, will only appear following clinical manifestations of CRS. It is not possible to detect the onset of CRS via these markers.

The majority of hospitals are unable to monitor cytokine levels in real-time; they are only able to observe clinical manifestations. The timescales around CRS occurring are impacted by a number of factors, for example, the patient’s disease state or type of CAR-T therapy.

CRS peaks on the 3rd and 7th day after administration of Kymriah, which includes the costimulatory domain of 4-1BB (CD137).

CRS occurs on the second day of administration of Yescarta or Tecartus, which includes the costimulatory domain of CD28. Some instances of delayed CRS were reported after three weeks of CAR-T administration, however.2

The American Society for Transplantation and Cell Therapy (ASTCT) established a CRS consensus grading guideline in 2019 (Table 2). This guideline states that fever (≥38 °C) is a requirement. Conditions become more severe, either with or without hypotension and/or hypoxia.

ASTCT grading

According to a number of studies, employing the ASTCT grading system provides an accurate, objective, and repeatable rapid clinical assessment of CRS clinically severity.2,3 A summary of the grading guideline is provided below.

Table 2. ASTCT CRS Consensus Grading. Source: ACROBiosystems

CAR-T Therapy: Syndrome Released by Cytokine

Grade 1

Grade 1 includes CRS patients displaying fever and some non-specific signs but without hypotension or hypoxia. Treatment strategies at this grade involve intravenous infusion of antipyretic drugs.

Grade 2

Grade 2 CRS is defined as fever (≥38.0 °C) with hypotension that does not require vasopressors and/or hypoxia that requires the use of oxygen delivered by blow-by or low-flow nasal cannula (≤6 L/minute).

It should be noted, however, that CRS patients are at risk of edema as a result of capillary leakage or vasodilatation and that fluid infusion should be closely monitored in order to avoid this.

Tocilizumab inhibits IL-6, and this can be used for Grade 2 patients. Early use of tocilizumab has been shown to reduce the prevalence of severe CRS and organ failure while maintaining CAR-T therapy efficacy.

Grade 3

Grade 3 CRS patients are those that exhibit low blood pressure, fever, and no response to fluid infusion. This grade also includes patients requiring high flow oxygen (≥6 L/min).

These patients should be considered for entry into an intensive care unit (ICU) for management and care, with Belizumab and glucocorticoids (dexamethasone, etc.) utilized for treatment.

It is recommended to use a vasopressor (such as norepinephrine) and/or high-flow nasal cannula (>6 L/minute) in order to reduce the risk of further deterioration and visceral damage. High-grade CRS patients are also prone to cardiac dysfunction, so the cardiac function should be closely monitored.

Grade 4

Grade 4 CRS patients are defined as having a fever (≥38.0 °C) with hypotension, necessitating the use of multiple vasopressors (excluding vasopressin) and/or hypoxia that requires positive pressure; for example, mechanical ventilation, bilevel positive airway pressure, CPAP, intubation. These symptoms should not be attributable to any other cause.

Methylprednisolone is recommended to use at a dose of 1 g/day in addition to any treatment for Grade 3 CRS. According to studies, high-grade CRS is reversible through appropriate early intervention.

Roche's drug tocilizumab (trade name: Actemra) was approved by the FDA in 2017. It has been designed for the CRS caused by CAR-T therapy, mitigating this by blocking the inflammatory cytokine interleukin-6 (IL -6).

Clinical guidance for tocilizumab4

A range of clinical guidance has been provided for tocilizumab. Tocilizumab should be considered in the early stage of CRS for elderly patients or those with severe complications. The drug can be administered for adults with Grade 2 CRS, as well as children with Grade 3 CRS. It can also be administered to pediatric patients developing Grade 2 CRS but intolerant to fever.

If adults and children are administered one dose of tocilizumab and conditions fail to improve, the second dose should be administered together with glucocorticoids. Should there continue to be no improvement, Siltuximab, Anakinra, and a high dose of methylprednisolone should be considered.

CRS treatment

Researchers continue to work hard on the mitigation and effective treatment of CRS. Prominent journal Nature published two articles on a new method of controlling CAR-T toxicity on the same day in 2018, outlining research that confirmed that inhibiting IL-1 can reduce macrophage-induced CRS.

An article was published in Science Translational Medicine in 2019 by Michel Sadelain, director of the Cell Engineering Center at Sloan Kettering Cancer Center. Within the article, he identified a functional switch in CAR-T cells that were found to help avoid CRS in mouse models.5

A research team from the Chinese Academy of Medical Sciences published an article in Science Immunology in January 2020, outlining the process of pyrolysis caused by CAR-T therapies, alongside the mechanism of CRS. Their clear microscope images confirmed that the whole process of CRS was triggered by CAR-T cell therapy.6

Significant breakthroughs can be anticipated soon, thanks to continuous clinical research into CRS and CAR-T therapies.

ACROBiosystems has developed a range of CAR-T target proteins, including EGFR, CD19, BCMA, CD22 MSLN. Each of these proteins is available in different forms such as non-labeled, fluorescent-labeled, and biotin-labeled. Flow cytometry protocols for CAR expression detection are also provided.

ACRO FITC-labeled CD19 protein (Cat. No. CD9-HF2H2) is highly sensitive and specific in anti-CD19 CAR detection assays. Another antibody is available (Cat. No. FM3-FY45), which targets the antigen-binding epitope of FMC63 scFv, therefore providing an additional means of Anti-CD19 (FMC63) CAR detection.

Furthermore, ACRO FITC-labeled BCMA protein (Cat. No. BCA-HF254) offers good sensitivity, is well-recognized, and has been used in a wide range of different assays.

Product list

Table 3. CD19. Source: ACROBiosystems

Table 3

Table 4. BCMA. Source: ACROBiosystems

Table 4

Table 5. Anti-FMC63 mAb. Source: ACROBiosystems

Table 5

Case study

Within this example study, 1e6 of anti-CD19 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human CD19 (20-291), His Tag (Cat. No. CD9-HP2H3). PE Streptavidin was utilized as a negative control.

CAR-T Therapy: Syndrome Released by Cytokine

Image Credit: ACROBiosystems

2e5 of Anti-CD19 CAR-293 cells were stained using 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) FITC-Labeled Monoclonal Anti-FMC63 scFv Antibody, Mouse IgG1 (Cat. No. FM3-FY45) and isotype control respectively. FITC signal was employed to evaluate binding activity.

CAR-T Therapy: Syndrome Released by Cytokine

Image Credit: ACROBiosystems

1e6 of the Anti-BCMA CAR-293 cells were stained using 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human BCMA Protein, His Tag (Cat. No. BCA-HP2H2) and negative control protein respectively. Here, PE signal was employed in order to evaluate binding activity.

CAR-T Therapy: Syndrome Released by Cytokine

Image Credit: ACROBiosystems

References and Further Reading

  1. https://www.cn-healthcare.com/articlewm/20190306/content-1047067.html.
  2. Schubert ML, Schmitt M, Wang L, et al. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann Oncol. 2021;32(1):34-48.
  3. Freyer CW, Porter DL. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies. J Allergy Clin Immunol. 2020;146(5):940-948.
  4. Maus MV, Alexander S, Bishop MR, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. J Immunother Cancer. 2020;8(2):e001511.
  5. Mestermann, Katrin, et al. "The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells." Science translational medicine 11.499 (2019).
  6. Liu, Yuying, et al. "Gasdermin E–mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome." Science immunology 5.43 (2020).

About ACROBiosystems

ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics. The company employs an application-oriented development strategy, with a particular focus on product design, quality control and solution-based support. Our products and services enable anyone in the field of drug development to have a more intuitive and streamlined process.

To respond to the coronavirus pandemic, ACROBiosystems has developed SARS-CoV-2 antigens specifically designed and optimized for serological test kits, including Spike-derived antigen S1, RBD and Nucleocapsid protein. Proteins have been supplied to diagnostic companies in large quantities.


Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Last updated: Feb 23, 2021 at 3:52 AM

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    ACROBiosystems. (2021, February 23). CAR-T Therapy: Syndrome Released by Cytokine. News-Medical. Retrieved on May 06, 2021 from https://www.news-medical.net/whitepaper/20210223/CAR-T-Therapy-Syndrome-Released-by-Cytokine.aspx.

  • MLA

    ACROBiosystems. "CAR-T Therapy: Syndrome Released by Cytokine". News-Medical. 06 May 2021. <https://www.news-medical.net/whitepaper/20210223/CAR-T-Therapy-Syndrome-Released-by-Cytokine.aspx>.

  • Chicago

    ACROBiosystems. "CAR-T Therapy: Syndrome Released by Cytokine". News-Medical. https://www.news-medical.net/whitepaper/20210223/CAR-T-Therapy-Syndrome-Released-by-Cytokine.aspx. (accessed May 06, 2021).

  • Harvard

    ACROBiosystems. 2021. CAR-T Therapy: Syndrome Released by Cytokine. News-Medical, viewed 06 May 2021, https://www.news-medical.net/whitepaper/20210223/CAR-T-Therapy-Syndrome-Released-by-Cytokine.aspx.

Other White Papers by this Supplier